Resection of chest wall invasion in patients with non-small cell lung cancer

Matsuoka, Hidehito; Nishio, Wataru; Okada, Morihito; Sakamoto, Toshihiko; Yoshimura, Masahiro; Tsubota, Noriaki
December 2004
European Journal of Cardio-Thoracic Surgery;Dec2004, Vol. 26 Issue 6, p1200
Academic Journal
Abstract: Objective: The treatment of patients with non-small cell lung cancer invading the parietal pleura or chest wall is still debated. It is unsolved whether the depth of chest wall involvement or the type of resection (extrapleural or en bloc) affects long-term survival. Methods: design, retrospective analysis; setting, Hyogo Medical Center for Adults, patients: the 97 patients who underwent surgical resection for non-small cell lung cancer involving the parietal pleura or chest wall between 1985 and 1997 were reviewed. Results: Of the 97 patients, 76 had apparently complete resection, 21 had incomplete resection. The overall 5-year survival of completely resected patients was 34.2%, and that of incompletely resected patients was 14.3% (P=0.0489). In complete resection cases, the chest wall involvement was limited to the parietal pleura in 40, extended into the subpleural soft tissues in 10, and extended into the ribs in 26. The 5-year survivals were 32.5, 30.0 and 38.5%, respectively (no significant difference). The 5-year survival of completely resected patients with T3 N0 M0 disease was 44.2%, T3 N1 M0 disease 40.0%, and T3N2 M0 disease 6.2% (P=0.0019). The 5-year survival of completely resected patients with extrapleural resections was 30.0%, that of en bloc resections 38.9% (no significant difference). Conclusions: Survival of patients with lung cancer invading the chest wall or parietal pleura after resection is highly dependent on the completeness of resection and the extent of nodal involvement, but not so much on the depth of chest wall invasion or type of resection.


Related Articles

  • Foreword.  // Current Medical Literature: Lung Cancer;2012, Vol. 5 Issue 3, preceding p65 

    An introduction to the journal is presented wherein the author discusses advances in the treatment of lung cancer and introduces review articles published within the issue.

  • ACCP publishes unprecedented lung cancer guidelines. LoBuono, Charlotte // Drug Topics;3/3/2003, Vol. 147 Issue 5, p26 

    Reports on the American College of Chest Physicians' (ACCP) publication of 'Diagnosis and Management of Lung Cancer: ACCP Evidence-Based Guidelines'. Update on the prevention, detection, diagnosis, staging and treatment of lung cancer patients; Advocacy of a multidisciplinary approach to the...

  • Foreword. Hansen, Heine H. // Current Medical Literature: Lung Cancer;2011, Vol. 4 Issue 3, preceding p69 

    A foreword to the volume 4, issue 3 of "Current Medical Literature – Lung Cancer" is presented, in which the editor discusses the association between smoking and lung cancer, advances in treatment, and types of articles in the issue.

  • Tumor volumes derived from PET/CT smaller than those derived from CT alone.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p23 

    The article discusses the findings from a phase-2 trial which showed that tumor volumes among patients with non-small cell lung cancer, positron emission tomography (PET)/computed tomography (CT) treated with radiation therapy are smaller than those from patients treated with CT alone, presented...

  • Thoracic radiotherapy plus paclitaxel/carboplatin effective with least toxicity in NSCLC.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p30 

    The article discusses the findings from a phase-3 trial which demonstrated the efficacy of concurrent thoracic radiotherapy combined with paclitaxel and carboplatin in patients with unresectable state III non-small cell lung cancer, presented at the 51st Annual Meeting of the American Society...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;8/4/2012, Issue 659, p11 

    The article reports on the growth in non-small cell lung cancer drug in China. .

  • Introduction. Bunn Jr., Paul A.; Thatcher, Nick // Oncologist;Jan2008 Supplement 1, Vol. 13, p1 

    Lung cancer is the most common cancer and a highly lethal disease, with improvements in survival rates being dependent on advances in early detection and improved systemic therapies applied to surgery and/or irradiation in early-stage disease. Non-small cell lung cancer (NSCLC) represents around...

  • A breath of fresh air: Lung cancer survival shows some improvement. Derrane, Mary // JNCI: Journal of the National Cancer Institute;12/02/98, Vol. 90 Issue 23, p1770 

    Deals with factors affecting the survival rate for lung cancer. Increase in the survival rates; Responsiveness of small-cell lung cancers to chemotherapy and radiation; Work on the early detection of lung cancer.

  • Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588... Sause, William T.; Scott, Charles // JNCI: Journal of the National Cancer Institute;2/1/95, Vol. 87 Issue 3, p198 

    Reports on the results of clinical trials conducted by the Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) using innovative radiation delivery techniques and the addition of chemotherapy in the treatment of non-small cell lung cancer. Acceptable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics